✦ LIBER ✦

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

✍ Scribed by Alexander MM Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro Testori; Wim Kruit; Cornelis JA Punt; Michelle Delauney; François Sales; Gerard Groenewegen; Dirk J Ruiter; Izabella Jagiello; Konstantin Stoitchkov; Ulrich Keilholz; Danielle Lienard

Book ID: 117290328
Publisher: The Lancet
Year: 2005
Tongue: English
Weight: 126 KB
Volume: 366
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(05)67482-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant therapy with pegylated interfer

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

✍ Alexander MM Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 236 KB

Two different durations of adjuvant ther

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

✍ Johan Hansson; Steinar Aamdal; Lars Bastholt; Yvonne Brandberg; Micaela Hernberg 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 283 KB

Health-related quality of life in patien

✍ Y. Brandberg; S. Aamdal; L. Bastholt; M. Hernberg; U. Stierner; H. von der Maase 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 419 KB

Final results of the EORTC 18871/DKG 80-

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis

✍ U.R. Kleeberg; S. Suciu; E.B. Bröcker; D.J. Ruiter; C. Chartier; D. Liénard; J. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 292 KB